US stem cell policy under fire from research group
This article was originally published in Clinica
President Bush's one-year-old stem cell policy is not living up to its limited promise, claims to the Coalition for the Advancement of Medical Research (CAMR). Since the President announced his policy on August 9 2001, only 17 of the 60 stem cell lines promised have become available to researchers and only one line owner is actually sharing its line with research labs, the group said.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.